Careen Shearin Foster, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1321 Colby Ave, Everett, WA 98201 Phone: 425-261-2000 |
Lawrence M. Schecter, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1321 Colby Ave, Everett, WA 98201 Phone: 425-261-4042 |
Kevin Farrell Montgomery, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 125 130th St Se, Everett, WA 98208 Phone: 425-385-2263 |
Michael Millie, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1330 Rockefeller Ave, Everett, WA 98201 Phone: 425-339-5442 |
William J Gallagher, MD Surgery Medicare: Medicare Enrolled Practice Location: 3216 Norton Ave, Suite 202, Everett, WA 98201 Phone: 425-297-5330 |
News Archive
Voalte, the leader in healthcare communication technology, today announced a new capital infusion of $17 million by Ascension Ventures, Cerner Capital, Inc., an affiliate of Cerner Corporation, and Bedford Funding. Series D funding closed on July 27, 2015, bringing the total capital Voalte has raised to nearly $60 million in three years.
IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, today announced the launch of the ARISk- Risk Assessment Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder.
A new study reveals how the production of a potent immune regulator called interferon gamma (IFNg) is controlled in natural killer (NK) cells, immune cells that typically defend the body against cancer and infections.
A study by a consultant paediatrician at Westmead Children's Hospital in Sydney has found that as many as one third of Australian women admit to drinking alcohol when pregnant, even though they know it could affect their unborn child.
BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
› Verified 6 days ago